MELK is not necessary for the proliferation of basal-like breast cancer cells

Thorough preclinical target validation is essential for the success of drug discovery efforts. In this study, we combined chemical and genetic perturbants, including the development of a novel selective maternal embryonic leucine zipper kinase (MELK) inhibitor HTH-01-091, CRISPR/Cas9-mediated MELK k...

Full description

Saved in:

Bibliographic Details
Published in:	eLife Vol. 6; no. 9, 2017
Main Authors:	Huang, Hai-Tsang, Seo, Hyuk-Soo, Zhang, Tinghu, Wang, Yubao, Jiang, Baishan, Li, Qing, Buckley, Dennis L, Nabet, Behnam, Roberts, Justin M, Paulk, Joshiawa, Dastjerdi, Shiva, Winter, Georg E, McLauchlan, Hilary, Moran, Jennifer, Bradner, James E, Eck, Michael J, Dhe-Paganon, Sirano, Zhao, Jean J, Gray, Nathanael S
Format:	Journal Article
Language:	English
Published:	England eLife Sciences Publications Ltd 19.09.2017 eLife Sciences Publications, Ltd
Subjects:	basal-like breast cancer Breast cancer Breast Neoplasms - pathology Cancer Biology Cell Biology Cell culture Cell cycle Cell Line, Tumor Cell Proliferation Clonal deletion CRISPR Drug discovery Embryogenesis Enzyme inhibitors Gene Knockdown Techniques Gene Knockout Techniques HTH-01-091 Humans Hypothesis testing Kinases Leucine zipper proteins Life sciences Medical research MELK OTSSP167 Protein-Serine-Threonine Kinases - analysis Protein-Serine-Threonine Kinases - antagonists & inhibitors Protein-Serine-Threonine Kinases - genetics Proteins RNA-mediated interference target validation Tumors basal-like breast cancer MELK cell biology HTH-01-091 target validation OTSSP167 cancer biology human
ISSN:	2050-084X, 2050-084X
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!

Be the first to leave a comment!